8-K: Cingulate Inc. Announces First Quarter 2025 Financial Results and Provides Update on ADHD and Anxiety Assets

Cingulate Inc. reported its Q1 2025 financial results, highlighted by a Pre-NDA meeting for CTx-1301 and a grant to accelerate CTx-2103 development.

Summary

• Cingulate Inc. announced its financial results for the quarter ended March 31, 2025, along with clinical and business updates.
• The company completed a Pre-NDA meeting with the FDA for CTx-1301, its lead ADHD asset, and remains on track to submit the NDA in mid-2025.
• Cingulate received a $3 million grant to accelerate the development of CTx-2103 for anxiety, payable in three installments.
• As of March 31, 2025, Cingulate had $9.5 million in cash and cash equivalents, providing a cash runway into the fourth quarter of 2025.
• Research and development expenses for the quarter were $2.2 million, an increase of $0.4 million compared to the same period in 2024.
• General and administrative expenses were $1.5 million, an increase of $0.3 million compared to the same period in 2024.
• The net loss for the quarter was $3.8 million, compared to $3.0 million for the same period in 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is progressing with its clinical programs and has secured non-dilutive funding, but it is also experiencing increasing losses and a decreasing cash position.

Positives

• The successful Pre-NDA meeting with the FDA for CTx-1301 keeps the company on track for a mid-2025 NDA submission.
• The $3 million grant for CTx-2103 development is non-dilutive funding and will cover development costs through mid-2026.
• Positive results from the food effect study of CTx-1301 provide flexibility in how patients can take the medication.
• The company's PTR platform technology has the potential to be applied to other therapeutic areas beyond ADHD and anxiety.

Negatives

• Cingulate experienced a net loss of $3.8 million for the quarter, an increase from $3.0 million in the same period last year.
• Cash and cash equivalents decreased by $2.7 million from December 31, 2024, to March 31, 2025.
• Working capital decreased from $7.7 million to $4.9 million during the same period.

Risks

• The company's cash runway extends only into the fourth quarter of 2025, raising concerns about future funding needs.
• The development of CTx-2103 is contingent on receiving milestone-based payments from the private foundation.
• The company's success depends on the FDA's approval of CTx-1301 and CTx-2103.
• The company faces competition in the ADHD and anxiety markets.

Future Outlook

Cingulate is targeting an NDA submission for CTx-1301 in mid-2025 and expects to file an IND for CTx-2103 by mid-2026.

Management Comments

• Chairman and CEO Shane J. Schaffer stated that the first quarter of 2025 was a very constructive one for Cingulate.
• He also noted that the company remains on target to file an NDA in the middle of the year for CTx-1301.

Industry Context

Cingulate is developing treatments for ADHD and anxiety, which are large and growing markets. The company's PTR platform technology aims to improve upon existing therapies by providing precise and controlled drug release.

Comparison to Industry Standards

• The $5.5 billion US anxiety market ($11.6 billion globally) highlights the significant commercial opportunity for CTx-2103.
• Competitors in the ADHD space include companies like Shire (now Takeda) with Vyvanse and Tris Pharma with Dyanavel XR, both extended-release stimulants.
• Cingulate's PTR platform aims to differentiate its products by providing a more controlled and predictable drug release profile compared to existing extended-release formulations.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss and decreasing cash position.
• Patients with ADHD and anxiety could benefit from the potential approval of CTx-1301 and CTx-2103.
• The company's employees are impacted by the reinstatement of base salaries.

Next Steps

• Submit the NDA for CTx-1301 in mid-2025.
• Conduct a formulation study of CTx-2103.
• Complete development batches required for the IND for CTx-2103.
• File an IND for CTx-2103 by mid-2026.

Key Dates

Keywords

CTx-1301, CTx-2103, ADHD, anxiety, NDA, PTR, buspirone, dexmethylphenidate, financial results, Cingulate